Can I take moboxetinib with ex20 mutation?

Non-small cell lung cancer is a serious threat to health and is primarily driven byEGFR mutations. Ex20ins mutations of EGFR are the third most common type of EGFR mutation and lead to abnormal activation of its tyrosine kinase domain, which favors tumor survival and confers resistance to most EGFR TKIs. Prior to the approval of Mobocertinib, treatment options for EGFR ex20ins-mutated NSCLC were limited.

The discovery of osimertinib, the first drug to treat the EGFR T790M mutation, involved the use of computer-assisted, structure-based drug design and careful tuning of thiol reactivity and binding affinity to EGFR ex20ins mutants. In a Phase 1 and 2 clinical study, mobosertinib effectively and selectively targeted EGFR ex20ins mutants and demonstrated excellent efficacy and safety. MobosetinibThe targeted approach to intervening in non-small cell lung cancer at the molecular level and the significant clinical benefits it provides to EGFR ex20ins-positive non-small cell lung cancer patients highlight its role in precision medicine.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.